A novel gene therapy nanomedicine is developed to treat iCCA in vivo by modulating PBRM1 expression, highlighting its crucial role in controlling iCCA and predicting prognosis. This evidence concerns the gene PBRM1 and infantile convulsions and choreoathetosis.